Literature DB >> 15588174

Antivenom dosing in 35 patients with severe brown snake (Pseudonaja) envenoming in Western Australia over 10 years.

Justin M Yeung1, Mark Little, Lindsay M Murray, George A Jelinek, Frank F S Daly.   

Abstract

OBJECTIVE: To investigate the doses of antivenom administered to adult patients with severe brown snake envenoming. DESIGN AND
SETTING: Review of charts from Western Australian adult teaching hospitals, December 1991 to December 2001. PATIENTS: 35 patients with severe brown snake envenoming, defined prospectively as afibrinogenaemia (< 0.3 g/L) after a bite by a brown snake (genus Pseudonaja). MAIN OUTCOME MEASURE: The dose of antivenom required to neutralise venom, defined prospectively as the dose of antivenom given before the return of detectable fibrinogen levels.
RESULTS: Of 88 patients with brown snake envenoming admitted over the 10 years, at least 35 had severe envenoming. Afibrinogenaemia persisted for 10 hours (range, 1.4-68 hours) after the first dose of antivenom; in four patients afibrinogenaemia lasted more than 24 hours. The dose of antivenom given before venom neutralisation ranged from one to 23 ampoules. In two-thirds of cases, venom was neutralised with five ampoules, and 89% had venom neutralised with 10 ampoules. Two patients died, and another had serious bleeding complications. Another patient died during the study period from intracerebral haemorrhage, but did not have fibrinogen levels measured.
CONCLUSIONS: Patients received initial doses of antivenom too small to neutralise circulating venom, and remained afibrinogenaemic for prolonged periods, with serious consequences. The authors now use 10 ampoules as an initial dose in severe brown snake envenoming.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15588174

Source DB:  PubMed          Journal:  Med J Aust        ISSN: 0025-729X            Impact factor:   7.738


  6 in total

1.  Clotting factor replacement and recovery from snake venom-induced consumptive coagulopathy.

Authors:  Simon G A Brown; Ngaire Caruso; Meredith L Borland; David L McCoubrie; Antonio Celenza; Geoffrey K Isbister
Journal:  Intensive Care Med       Date:  2009-06-23       Impact factor: 17.440

2.  Early prediction of acute kidney injury by clinical features of snakebite patients at the time of hospital admission.

Authors:  Jayanta Paul; Somnath Dasgupta
Journal:  N Am J Med Sci       Date:  2012-05

3.  Clinical effects and antivenom dosing in brown snake (Pseudonaja spp.) envenoming--Australian snakebite project (ASP-14).

Authors:  George E Allen; Simon G A Brown; Nicholas A Buckley; Margaret A O'Leary; Colin B Page; Bart J Currie; Julian White; Geoffrey K Isbister
Journal:  PLoS One       Date:  2012-12-28       Impact factor: 3.240

4.  Dosage comparison of snake anti-venomon coagulopathy.

Authors:  Ali Hassan Rahmani; Amir Jalali; Mohammad Hassan Alemzadeh-Ansari; Mina Tafazoli; Fakher Rahim
Journal:  Iran J Pharm Res       Date:  2014       Impact factor: 1.696

5.  Dose of antivenom for the treatment of snakebite with neurotoxic envenoming: Evidence from a randomised controlled trial in Nepal.

Authors:  Emilie Alirol; Sanjib Kumar Sharma; Anup Ghimire; Antoine Poncet; Christophe Combescure; Chabilal Thapa; Vijaya Prasad Paudel; Kalidas Adhikary; Walter Robert Taylor; David Warrell; Ulrich Kuch; François Chappuis
Journal:  PLoS Negl Trop Dis       Date:  2017-05-16

6.  The Snake Study: Survey of National Attitudes and Knowledge in Envenomation.

Authors:  George Braitberg; Vasilios Nimorakiotakis; Celene Y L Yap; Violet Mukaro; Ronelle Welton; Anna Parker; Jonathan Knott; David Story
Journal:  Toxins (Basel)       Date:  2021-07-12       Impact factor: 4.546

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.